Bioinformatics business GenomeNext has raised a $1.2 million seed funding round to expand commercial and operational capacity and to support product development, according to Co-founder and CEO James Hirmas in a company statement. It is part of a wider trend of companies developing technologies to support precision medicine and to enable population scale genomics.
The technology at the heart of its business was developed at Nationwide Children’s Hospital. It is designed to solve “computational bottlenecks and inherent inaccuracies” of traditional genomic sequence analysis, a company statement said. The goal is to help clinicians and researchers identify rare pathogenic variants.
Canadian investor Hydra Capital led the seed round with participation from private investors. Among the company’s partners are Intel and Amazon.
Integrating GLP-1s: How Berry Street is Redefining Nutrition Care
Richard Fu details the company's approach to nutrition therapy and strategy for patients using GLP-1s.
Bioinformatics has been a growing area of interest, particularly as a way to support research. Among some of the companies active in this segment are SolveBio.